388582-22-7

Upstream product

• 83552-81-2 <1-13C>-phenylacetonitrile 
• 100-39-0 benzyl bromide 

Downstream Products

• 1214272-01-1 methyl [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)[2-(13C)]pyrimidin-5-yl]acetate 
• 1214271-91-6 [4,6-bis(dimethylamino)-2-(4-{[4-(trifluoromethyl)benzoyl]amino}benzyl)-[2-(13C)]pyrimidin-5-yl]acetic acid 
• 1214272-00-0 methyl [2-(4-aminobenzyl)-4,6-bis(dimethylamino)-[2-(13C)]pyrimidin-5-yl]acetate 
• 1214271-99-4 methyl [4,6-bis(dimethylamino)-2-(4-nitrobenzyl)-[2-(13C)]pyrimidin-5-yl]acetate 
• 1214271-98-3 methyl [4,6-dichloro-2-(4-nitrobenzyl)-[2-(13C)]pyrimidin-5-yl]acetate 
• 1214271-97-2 methyl [4,6-dihydroxy-2-(4-nitrobenzyl)-[2-(13C)]pyrimidin-5-yl]acetate 
• 1214271-96-1 2-(4-nitrophenyl)-[1-(13C)]ethanimidamide hydrochloride 

Relevant academic research and scientific papers

Preparation of [carboxy-13C]4-nitrophenylacetic acid

Reaction of sodium [13C]cyanide with excess benzyl chloride gave ～75% utilization of the isotope. Subsequent nitration, isomer separation and hydrolysis of the nitrile gave the required carboxy-labelled 4-nitrophenylacetic acid. Copyright

ISOTOPICALLY ENRICHED PYRIMIDIN-5-YL ACETIC ACID DERIVATIVES AS CRTH2 ANTAGONISTS

Provided herein are 2H- and 13C-enriched compounds of formula (I) or (II); wherein R is as defined herein, and wherein at least one hydrogen atom, in certain embodiments, three or more hydrogen atoms, are deuterium atoms or at least one carbon atom is a carbon-13 atom. Also provided are pharmaceutical compositions and methods using the 2H- and 13C-enriched compounds, useful for treating CRTH2-related diseases or disorders such as, for example, asthma, allergic rhinitis, atopic dermatitis, allergic conjuvatitis, Churg-Strauss syndrome, sinusitis, basophilic leukemia, chronic urticaria or basophilic leukocytosis.

Relative migratory aptitudes of hydrogen, benzoyl, 4-methoxyphenyl and 4-nitrophenyl groups in some unsaturated carbenes (vinylidenes)

([5-13C] Tetrazol-5-yl)methyl ketones were prepared and subjected to oxidative fragmentation induced by lead tetraacetate. The resulting intermediate [1-13C]-3-oxoprop-1-en-1-ylidenes rearrange, depending on the relative migratory aptitudes of the benzoyl group and the ligands R, either to [3-13C]prop-2-yn-1-ones or to [2-13C]prop-2-yn-1-ones or to mixtures of the two isomers. The 1H and/or 13C NMR spectra of the products allow the three cases to be distinguished. The relative migratory aptitudes were found to be H>PhCO, 4-MeOC6H4>4-O2NC6H 4.